Correction: Tumor-penetrating peptide boosts bispecific T-cell engager antitumor efficacy for the pancreatic cancer
Lu Zou, Jingjing Chen, Xinyuan Bai, Yingxin Wang, Changchang Lu, Qiaoli Wang, Subiyinuer Tuerhong, Mengzhu Li, Qinghua Zheng, Fanyan Meng, Juan Du
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsMonoclonal and Polyclonal Antibodies Research · CAR-T cell therapy research · Immunotherapy and Immune Responses
An incorrect Funding statement was provided. The correct funder is “the National Natural Science Foundation of China (No. 82373280), Key Project supported by Medical Science and technology development Foundation, Nanjing Department of Health (ZKX24021 and YKK24072), the provincial key medical disciplines during the “14th Five-Year Plan” period (ZDXK202233) and 2024 Annual Medical Research Projects of the Jiangsu Provincial Health Commission (K2024038)”.
The original version of this article has been updated.